Rumination Disorder

Categories: Mental diseases, Rare diseases

Aliases & Classifications for Rumination Disorder

MalaCards integrated aliases for Rumination Disorder:

Name: Rumination Disorder 12 53 15
Psychogenic Rumination 12 73
Rumination Syndrome 76 53
Feeding and Eating Disorders of Childhood 44
Rumination Disorders 73


External Ids:

Disease Ontology 12 DOID:11507
ICD9CM 35 307.53
MeSH 44 D019959
NCIt 50 C92567
SNOMED-CT 68 37941009

Summaries for Rumination Disorder

NIH Rare Diseases : 53 Rumination disorder is the backward flow of recently eaten food from the stomach to the mouth. The food is then re-chewed and swallowed or spat out. A non-purposeful contraction of stomach muscles is involved in rumination. It may be initially triggered by a viral illness, emotional distress, or physical injury. In many cases, no underlying trigger is identified. Behavioral therapy is the mainstay of treatment.   .

MalaCards based summary : Rumination Disorder, also known as psychogenic rumination, is related to eating disorder and fungal esophagitis. An important gene associated with Rumination Disorder is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Ion channel transport and Serotonergic synapse. The drugs Naltrexone and Baclofen have been mentioned in the context of this disorder. Affiliated tissues include skin and colon, and related phenotype is homeostasis/metabolism.

Disease Ontology : 12 An eating disorder that is characterized by effortless regurgitation of most meals following consumption.

Wikipedia : 76 Rumination syndrome, or Merycism, is an under-diagnosed chronic motility disorder characterized by... more...

Related Diseases for Rumination Disorder

Diseases related to Rumination Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 eating disorder 11.0
2 fungal esophagitis 10.2 ATP12A ATP4A
3 diclofenac allergy 10.2 ATP12A ATP4A
4 gastroduodenal crohn's disease 10.2 ATP12A ATP4A
5 neonatal candidiasis 10.2 ATP12A ATP4A
6 photoallergic dermatitis 10.2 ATP12A ATP4A
7 squamous papillomatosis 10.2 ATP12A ATP4A
8 toxic megacolon 10.2 ATP12A ATP4A
9 aspiration pneumonitis 10.2 ATP12A ATP4A
10 gastrointestinal neuroendocrine benign tumor 10.2 ATP12A ATP4A
11 gastric antral vascular ectasia 10.2 ATP12A ATP4A
12 granulomatous gastritis 10.2 ATP12A ATP4A
13 esophageal candidiasis 10.2 ATP12A ATP4A
14 gastric neuroendocrine neoplasm 10.2 ATP12A ATP4A
15 acute laryngitis 10.2 ATP12A ATP4A
16 laryngitis 10.2 ATP12A ATP4A
17 duodenitis 10.2 ATP12A ATP4A
18 active peptic ulcer disease 10.2 ATP12A ATP4A
19 congenital disorder of deglycosylation 10.2 ATP12A ATP4A
20 bladder calculus 10.2 ATP12A ATP4A
21 ischemic neuropathy 10.2 ATP12A ATP4A
22 bile reflux 10.2 ATP12A ATP4A
23 capillary disease 10.2 ATP12A ATP4A
24 peptic esophagitis 10.2 ATP12A ATP4A
25 dyskinesia of esophagus 10.2 ATP12A ATP4A
26 hernia, hiatus 10.2 ATP12A ATP4A
27 anismus 10.2 ATP12A ATP4A
28 postsurgical hypothyroidism 10.2 ATP12A ATP4A
29 lymphocytic colitis 10.2 ATP12A ATP4A
30 esophageal atresia/tracheoesophageal fistula 10.2 ATP12A ATP4A
31 clostridium difficile colitis 10.2 ATP12A ATP4A
32 diarrhea 1, secretory chloride, congenital 10.2 ATP12A ATP4A
33 microscopic colitis 10.2 ATP12A ATP4A
34 laryngeal tuberculosis 10.2 ATP12A ATP4A
35 chronic laryngitis 10.2 ATP12A ATP4A
36 eosinophilic gastritis 10.2 ATP12A ATP4A
37 esophagus adenocarcinoma 10.2 ATP12A ATP4A
38 chronic intestinal vascular insufficiency 10.2 ATP12A ATP4A
39 polyposis, skin pigmentation, alopecia, and fingernail changes 10.2 ATP12A ATP4A
40 jejunoileitis 10.2 ATP12A ATP4A
41 pancreatic steatorrhea 10.2 ATP12A ATP4A
42 esophageal varix 10.2 ATP12A ATP4A
43 duodenal disease 10.2 ATP12A ATP4A
44 gastric lymphoma 10.2 ATP12A ATP4A
45 lower urinary tract calculus 10.2 ATP12A ATP4A
46 aspiration pneumonia 10.2 ATP12A ATP4A
47 blind loop syndrome 10.2 ATP12A ATP4A
48 pneumatosis cystoides intestinalis 10.1 ATP12A ATP4A
49 lateral medullary syndrome 10.1 ATP12A ATP4A
50 microinvasive gastric cancer 10.1 ATP12A ATP4A

Graphical network of the top 20 diseases related to Rumination Disorder:

Diseases related to Rumination Disorder

Symptoms & Phenotypes for Rumination Disorder

MGI Mouse Phenotypes related to Rumination Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.17 ACHE ATP12A ATP4A GJB2 HTR1A HTR3A

Drugs & Therapeutics for Rumination Disorder

Drugs for Rumination Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Baclofen Approved Phase 4 1134-47-0 2284
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
Citalopram Approved Phase 4,Phase 1 59729-33-8 2771
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 148553-50-8 5486971
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
Ziconotide Approved Phase 4 107452-89-1 447451
8 Narcotic Antagonists Phase 4,Phase 2,Early Phase 1
9 Narcotics Phase 4,Phase 2,Not Applicable,Early Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antidepressive Agents Phase 4,Phase 3,Phase 1,Not Applicable
12 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Nicotinic Agonists Phase 4,Not Applicable
15 Central Nervous System Stimulants Phase 4,Not Applicable
16 Cholinergic Agents Phase 4,Phase 1,Not Applicable
17 Autonomic Agents Phase 4,Phase 1,Not Applicable
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 1,Not Applicable
19 Muscarinic Antagonists Phase 4,Phase 1
20 Antiparkinson Agents Phase 4,Phase 1
21 Cholinergic Antagonists Phase 4,Phase 1
22 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Not Applicable
23 Antidepressive Agents, Second-Generation Phase 4,Phase 1,Not Applicable
24 Serotonin Uptake Inhibitors Phase 4,Phase 1,Not Applicable
25 Serotonin Agents Phase 4,Phase 1,Not Applicable
26 Parasympatholytics Phase 4,Phase 1
27 Analgesics, Non-Narcotic Phase 4,Phase 2
28 Calcium, Dietary Phase 4,Phase 3,Not Applicable
29 calcium channel blockers Phase 4,Phase 3,Not Applicable
30 Anti-Anxiety Agents Phase 4,Phase 3,Not Applicable
31 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Not Applicable
32 Anticonvulsants Phase 4,Phase 3,Not Applicable
33 Tranquilizing Agents Phase 4,Phase 3,Not Applicable
34 Adrenergic Agents Phase 4,Phase 2
35 omega-Conotoxins Phase 4
36 Pharmaceutical Solutions Phase 4,Not Applicable
37 Neuroprotective Agents Phase 4
38 Protective Agents Phase 4,Not Applicable
Serotonin Investigational, Nutraceutical Phase 4,Phase 1,Not Applicable 50-67-9 5202
Histamine Approved, Investigational Phase 3,Phase 1 51-45-6, 75614-87-8 774
Ketotifen Approved Phase 3 34580-14-8, 34580-13-7 3827
42 Vaccines Phase 3,Early Phase 1
43 Histamine Antagonists Phase 3,Phase 1
44 Anti-Allergic Agents Phase 3,Phase 1
45 Antipruritics Phase 3,Phase 1
46 Dermatologic Agents Phase 3,Phase 1
Histamine Phosphate Phase 3,Phase 1 51-74-1 65513
48 Histamine H1 Antagonists Phase 3,Phase 1
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0

Interventional clinical trials:

(show top 50) (show all 302)
# Name Status NCT ID Phase Drugs
1 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
2 Baclofen for Rumination Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
3 Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study) Completed NCT02816138 Phase 4 Nicotine
4 Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO) Recruiting NCT03128021 Phase 4 Escitalopram Pill;Levomilnacipran Pill
5 Ziconotide as First-Line IDT Recruiting NCT03321955 Phase 4 Ziconotide 100 MCG(microgram)/ML Intrathecal Solution
6 Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Terminated NCT01603394 Phase 4 pregabalin
7 Comparison of Diaphragmatic Breathing and Muscle Relaxation for Rumination Completed NCT01576302 Phase 3
8 A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV Completed NCT00529971 Phase 3
9 Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual Completed NCT00472862 Phase 3
10 Surgical Pain After Inguinal Hernia Repair (SPAIHR) Completed NCT00551135 Phase 3 Pregabalin;placebo;Pregabalin;Pregabalin
11 Effects of Cerebral and Peripheral Electrical Stimulation on Conditioned Pain Modulation in Healthy Subjects. Recruiting NCT03752502 Phase 2, Phase 3
12 Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance Active, not recruiting NCT02190968 Phase 3
13 PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2 Not yet recruiting NCT03582176 Phase 3 Lactose Placebo;Ketotifen Fumarate 2mg;Ketotifen Fumarate 5mg
14 Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression Completed NCT00577070 Phase 2
15 Web-based Support to Manage Arthritis Pain Completed NCT01463189 Phase 2
16 Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception Completed NCT00351819 Phase 2 AndroGel
17 Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury Completed NCT02684669 Phase 2 Naloxone;Normal saline
18 Memory Flexibility Training for Depression Completed NCT02371291 Phase 1, Phase 2
19 Exercise in Women With Fibromyalgia Completed NCT01490281 Phase 2
20 MemFlex to Prevent Depressive Relapse Recruiting NCT02614326 Phase 2
21 Effect of High-dose Naloxone Following Third Molar Extraction Recruiting NCT02976337 Phase 2 Naloxone;Normal Saline
22 Biopsychosocial Influence on Shoulder Pain Recruiting NCT02620579 Phase 2 Propranolol LA (60 mg);Placebo
23 The Modular Protocol for Mental Health (MPMH) Enrolling by invitation NCT03143634 Phase 1, Phase 2
24 Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems Unknown status NCT02498132 Phase 1
25 Rumination-focused CBT Training for the Prevention of Depression and Anxiety Completed NCT01223677 Phase 1
26 Pilot Study of Behavioral Activation for Prolonged Grief Completed NCT01556048 Phase 1
27 Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression Completed NCT00787501 Phase 1 SSRI
28 Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders Completed NCT02150681 Phase 1
29 A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder Completed NCT02476058 Phase 1 JNJ-42847922;Diphenhydramine;Placebo
30 Treatment Outcome in Major Depressive Disorder Recruiting NCT02869035 Phase 1 Escitalopram;Duloxetine
31 Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients Unknown status NCT03039387 Not Applicable
32 Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure Unknown status NCT02658682 Not Applicable
33 The Use of Resting State, fMRI and DTI in the Identification of Chronic Pain Conditions Unknown status NCT02987933
34 MEG Study of Mindfulness Based Stress Reduction Unknown status NCT00571051 Not Applicable
35 The Effect of Attention Bias Modification Training on Reducing Depressive Symptoms Unknown status NCT01628016 Not Applicable
36 Evaluation of the Impact of the Level of Mindfulness on the Management of Patients With Recurrent Depressive Disorders by the Mindfulness Based Cognitive Therapy ( MBCT ): an Exploratory Study Unknown status NCT02872324 Not Applicable
37 Attention Bias Modification Treatment for Major Depression Disorder in Adolescents Unknown status NCT02078258 Not Applicable
38 Evaluation of Yoga for Substance Use Risk Factors in a School Setting Unknown status NCT01821950 Not Applicable
39 Health Enhancement And Resilience Training Unknown status NCT01959126 Not Applicable
40 Influence of a Biopsychosocial Educational Internet-based Intervention in Chronic Low Back Pain Patients: A Mixed Methods Approach Unknown status NCT02369120 Not Applicable
41 Efficacy of Acceptance and Commitment Therapy (ACT) in Group in Fibromyalgia Unknown status NCT01611831 Not Applicable
42 Efficacy Study of Cognitive Behavioural Treatment With Support on Communication and Information Technologies for the Management of Chronic Low Back Pain Unknown status NCT01802671 Not Applicable
43 Fitness, Cellular Aging, and Caregiver Stress Study Unknown status NCT01993082 Not Applicable
44 Efficacy of Pain Neurophysiology Education in Combination With Psychologic Inoculation in Chronic Whiplash Unknown status NCT01544075 Early Phase 1
45 Mindfulness for Older Adults With Cognitive Concerns Unknown status NCT02902692 Not Applicable
46 Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression Completed NCT02278224 Not Applicable
47 Repetitive Thoughts in Fibromyalgia: Impact of Rumination on the Emotional and Cognitive Dimensions of Fibromyalgia Completed NCT03133455 Not Applicable
48 Treatment of Rumination by Biofeedback - a Randomized Controlled Trial Completed NCT02214472 Not Applicable Placebo
49 Placebo-controlled, Randomized Trial of a Simplified Biofeedback Technique for the Treatment of Rumination Completed NCT02402946 Not Applicable Placebo
50 The Study of Effectiveness of rTMS on Anhedonia and Rumination in Patients With MDD Completed NCT03468686 Not Applicable

Search NIH Clinical Center for Rumination Disorder

Cochrane evidence based reviews: feeding and eating disorders of childhood

Genetic Tests for Rumination Disorder

Anatomical Context for Rumination Disorder

MalaCards organs/tissues related to Rumination Disorder:

Skin, Colon

Publications for Rumination Disorder

Articles related to Rumination Disorder:

# Title Authors Year
Development of the Pica, ARFID, and Rumination Disorder Interview, a multi-informant, semi-structured interview of feeding disorders across the lifespan: A pilot study for ages 10-22. ( 30312485 )
Rumination Disorder: An Unexplained Case of Recurrent Vomiting. ( 28615777 )
Case report: recognizing first onset of rumination disorder in adults. ( 16950385 )
Overview of the treatment of rumination disorder for adults in a residential setting. ( 9627823 )
Merycism or rumination disorder. A historical investigation and current assessment. ( 7994499 )
Rumination disorder: differential diagnosis. ( 3288612 )

Variations for Rumination Disorder

Expression for Rumination Disorder

Search GEO for disease gene expression data for Rumination Disorder.

Pathways for Rumination Disorder

Pathways related to Rumination Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
11.83 ATP12A ATP4A HTR3A
2 11.19 HTR1A HTR3A HTR7
3 10.25 HTR1A HTR3A HTR7

GO Terms for Rumination Disorder

Cellular components related to Rumination Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.7 ATP12A ATP4A GJB2 HTR1A HTR3A HTR7
2 membrane GO:0016020 9.56 ACHE ATP12A ATP4A GJB2 HTR1A HTR3A
3 plasma membrane GO:0005886 9.17 ACHE ATP12A ATP4A GJB2 HTR1A HTR3A

Biological processes related to Rumination Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.63 HTR1A HTR3A HTR7
2 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.51 HTR1A HTR7
3 potassium ion import across plasma membrane GO:1990573 9.49 ATP12A ATP4A
4 potassium ion import GO:0010107 9.48 ATP12A ATP4A
5 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.43 HTR1A HTR7
6 ATP hydrolysis coupled proton transport GO:0015991 9.4 ATP12A ATP4A
7 cellular sodium ion homeostasis GO:0006883 9.37 ATP12A ATP4A
8 vasoconstriction GO:0042310 9.32 HTR1A HTR7
9 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.26 ATP12A ATP4A
10 cellular potassium ion homeostasis GO:0030007 9.16 ATP12A ATP4A
11 sodium ion export across plasma membrane GO:0036376 8.96 ATP12A ATP4A
12 serotonin receptor signaling pathway GO:0007210 8.62 HTR1A HTR3A

Molecular functions related to Rumination Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.32 HTR1A HTR7
2 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR7
3 sodium:potassium-exchanging ATPase activity GO:0005391 9.16 ATP12A ATP4A
4 serotonin binding GO:0051378 8.96 HTR1A HTR3A
5 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Rumination Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....